About this trial
Women's physiology changes markedly during normal pregnancy. The most distinct alterations occur in the hormonal and cardiovascular systems. There is a dramatic increase in both estrogen and progesterone. Blood volume starts to increase in the first gestational period and reaches a peak in the third trimester.
The physiologic ocular changes during pregnancy are mainly the result of hormonal and blood volume increase, and then are usually marked in the third trimester.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Healthy pregnant women
Age > 18 years
Gestational age < 12 weeks
Written informed consent
Disqualifiers
High risk pregnancy such as multifetal pregnancy and preeclampsia
History of vitreoretinal diseases such as retinal vasculitis
History of intraocular laser treatments or intraocular surgeries
History of systemic diseases such as diabetes mellitus and thyroid disease
Trial design
Single group
Treatments tested in this trial
Optical coherence tomography and optical coherence tomography angiography (Optovue®)
DeviceOptical coherence tomography and optical coherence tomography angiography (Optovue®) were performed in each trimesters and at 6 weeks after childbirth. 1. st trimester : gestational age 8-12 weeks 2. nd trimester : gestational age 24-28 weeks 3. rd trimester : gestational age 34-38 weeks
Treatment groups
Trial outcomes
Primary outcomes
Retinal vascular density
% of retinal vascular density is measured by optical coherence tomography angiography
Secondary outcomes
Choroidal thickness
Choroidal thickness (um) is measured by optical coherence tomography
Retinal nerve fiber layer thickness
Retinal nerve fiber layer thickness (um) is measured by optical coherence tomography
Optic disc tomography
Cup area and disc area (mm3) are measured by optical coherence tomography
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: